Human Milk Oligosaccharides (HMO) 乐鱼体育官网 Size
| Study Period | 2019 - 2030 |
| 乐鱼体育官网 Size (2025) | USD 237.01 Million |
| 乐鱼体育官网 Size (2030) | USD 608.41 Million |
| CAGR (2025 - 2030) | 20.75% |
| Fastest Growing 乐鱼体育官网 | Asia Pacific |
| Largest 乐鱼体育官网 | Asia-Pacific |
| 乐鱼体育官网 Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Human Milk Oligosaccharides (HMO) 乐鱼体育官网 Analysis
The Global Human Milk Oligosaccharides 乐鱼体育官网 size is estimated at USD 237.01 million in 2025, and is expected to reach USD 608.41 million by 2030, at a CAGR of 20.75% during the forecast period (2025-2030).
Human Milk Oligosaccharides (HMOs) are complex sugars available in human milk. They are the 3rd largest solid component in breast milk after fat and lactose and have no nutritive function. HMOs are responsible for directly stimulating the immune system by promoting good gut bacteria, strengthening the gut barrier function, and blocking pathogens. Changing consumer lifestyles and their increasing concerns regarding health and wellness are some of the other prominent factors driving the demand for HMOs around the world. Human milk oligosaccharides in functional food and beverage products and food supplements can help the treatment of certain disorders and high-risk health conditions, which in turn is anticipated to boost the product demand. Human milk oligosaccharides constitute a significant source of sialic acid, which is an essential part of the plasma membrane of nerve cells. Over 150 structurally diverse HMOs are available in nature. Moreover, scientists have been trying to develop various structures of HMOs synthetically for use in the food industry-most, particularly infant formulas and medical nutrition. These synthetically produced HMOs are safe for consumption by infants (who cannot be breastfed), as well as children and adults.
Human milk oligosaccharides find application in infant formula, functional food and beverages, and food supplements. Increasing health awareness and the rising consumption of infant formula are likely to boost the growth of the HMO 乐鱼体育官网 over the forecast period. The consumption of HMOs has contributed significantly catering to the rising concerns regarding health and safety, which are likely to boost 乐鱼体育官网 growth over the forecast period. HM, and Os play a key role in the proper development of infants. They fight life-threatening infections and are also responsible for properly developing the brain and gut.
Human Milk Oligosaccharides (HMO) 乐鱼体育官网 Trends
Increasing Awareness About The Health Benefits Associated With HMO
Good nutrition helps build the foundation for a child's ability to learn, grow and thrive. For babies, the best nutrition is breast milk due to special prebiotics called human milk oligosaccharides (HMOs). They are the largest solid component of breast milk after carbohydrates and fat. Various clinical data in infants indicate that Human Milk Oligosaccharide helps to develop the desired microbiota by serving as a food source for the good bacteria in the intestine. Naturally occurring in breast milk, HMOs have evolved over thousands of years. HMO research (clinical and preclinical) suggests that specific HMOs at the correct level of supplementation can provide babies with unique health benefits. In particular, Human Milk Oligosaccharide supports immunity and gut health, with a potential role in cognitive development, which may open future innovation opportunities and thus, would increase the demand for HMOs globally. According to research conducted by Abbott Nutrition, a specific HMO, 2'-FL or 2'-Fucosyllactose, can provide health benefits to a growing baby and plays a role in supporting the development of a strong immune system.
For instance, in July 2021, Inbiose, one of the leading biotech companies active in the development of Human Milk Oligosaccharides (HMOs), announced that it submitted its application for a Generally Recognized as Safe (GRAS) approval by the US Food & Drug Administration (FDA) of four HMOs, specifically 6'-Sialyllactose (6'SL), 3-Sialyllactose (3'SL), Lacto-N-Tetraose (LNT) and Lacto-N-neoTetraose (LNnT). Inbiose announced that it would also file for Novel Food approval of these HMOs by the European Commission (EFSA) and is preparing a global regulatory roll-out. Inbiose planned to obtain regulatory approval for these HMOs in 2022 and was currently organizing its industrial production in infant nutrition, dietary supplements, and functional food and beverages.
Asia-Pacific Holds a Singnificant Share in the 乐鱼体育官网
Asia-Pacific accounts for a significant 乐鱼体育官网 share; wherein, 乐鱼体育官网 growth includes an ever-expanding reach in infant formulas and functional beverages, the rise of the dairy industry, and rapid technological advancements in the product line. In addition, changes in lifestyles focused on nutritious foods are likely to increase the need for products. Among all the applications, the use in infant formulas registers significant participation with the rise in the inclusion of HMO in prebiotics in terms of volume for this 乐鱼体育官网. Human Milk Oligosaccharides (HMO) respect the prebiotic properties as it helps develop commensal bacteria and the increasing demand for functional food, and dietary supplements for better health and digestion, the 乐鱼体育官网 for HMO is expected to grow in the region during the forecast period.
Another factor boosting the human milk oligosaccharides 乐鱼体育官网 in Japan is the desire for high-nutrition foods and digestive supplements among both children and adults. HMOs, enhance metabolic activity by promoting bacterial growth in the stomach, particularly in the Bifidobacterium species. Japanese consumers have been very conscious about regularly replenishing the bacterial flora in their gut and perceive probiotic bacteria to be the best solution, which is further driving the 乐鱼体育官网 in the country.
Human Milk Oligosaccharides (HMO) Industry Overview
The global human milk oligosaccharides 乐鱼体育官网 is highly competitive with prominent players such as Koninklijke DSM N.V., Chr. Hansen Holding A/S, BASF SE, Inbiose NV, and International Flavors & Fragrances Inc. (DuPont). The major companies are investing highly in R&D, to develop products with similar health benefits as that of breast milk. Key strategies adopted by players in the 乐鱼体育官网 are product partnerships for extended research activities and new product launches. Key players established unique sales and distribution networks through partnerships with local establishments or offering products via interactive e-commerce channels to reach a wide range of consumers and expand into untapped 乐鱼体育官网s.
Human Milk Oligosaccharides (HMO) 乐鱼体育官网 Leaders
-
Koninklijke DSM N.V.
-
Chr. Hansen Holding A/S
-
BASF SE
-
Inbiose NV
-
International Flavors & Fragrances Inc. (DuPont)
- *Disclaimer: Major Players sorted in no particular order
Human Milk Oligosaccharides (HMO) 乐鱼体育官网 News
- In November 2022, Kyowa Hakko Bio Co. Ltd (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), completed a production facility for human milk oligosaccharides (HMOs) at its Thai subsidiary, Thai Kyowa Biotechnologies Co, Ltd.
- In October 2022, FrieslandCampina's 2'-fucosyllactose trademarked Aequival was approved by Australia's and New Zealand's authorities for use in infant milk formula. The company is on track to expand its human milk oligosaccharide (HMO) portfolio with the launch of Lacto-N-tetraose (LNT), 3-fucosyllactose (3-FL), 3'-Sialyllactose (3'-SL), and SL), and 6-Sialyllactose (6-SL). It helps establish the infant's gut microbiota and metabolism, while others can prevent pathogens from attaching to intestinal cells and causing infection.
- In March 2021, BASF announced that PREBILAC, BASF's brand of 2'-FL, had received approval from Australia's Therapeutic Goods Administration (TGA), making it the first and only 2'-FL ingredient to receive TGA approval as a prebiotic ingredient.
Human Milk Oligosaccharides (HMO) Industry Segmentation
Human Milk Oligosaccharides (HMOs) as a functional ingredient extracted from human breast milk act as inflammatory and immune modulators. They act as nutrients for the neurological development of infants. The Human Milk Oligosaccharides 乐鱼体育官网 is segmented into application and geography. By application, the 乐鱼体育官网 is segmented into infant formula, dietary supplements, and functional food and beverage. The geographical analysis of the 乐鱼体育官网 has also been included in the study. By geography, the 乐鱼体育官网 is further segmented into North America, Europe, Asia-Pacific, and Rest of the World. For each segment, the 乐鱼体育官网 sizing and forecasts have been done on the basis of value (in USD million).
| Application | Infant Formula | ||
| Dietary Supplements | |||
| Functional Food and Beverage | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Rest of North America | |||
| Europe | Germany | ||
| Spain | |||
| United Kingdom | |||
| France | |||
| Rest of Europe | |||
| Asia Pacific | China | ||
| Japan | |||
| Australia | |||
| Rest of Asia-Pacific | |||
| Rest of the World | South America | ||
| Middle East and Africa | |||
| Infant Formula |
| Dietary Supplements |
| Functional Food and Beverage |
| North America | United States |
| Canada | |
| Mexico | |
| Rest of North America | |
| Europe | Germany |
| Spain | |
| United Kingdom | |
| France | |
| Rest of Europe | |
| Asia Pacific | China |
| Japan | |
| Australia | |
| Rest of Asia-Pacific | |
| Rest of the World | South America |
| Middle East and Africa |
Human Milk Oligosaccharides (HMO) 乐鱼体育官网 Research FAQs
How big is the Global Human Milk Oligosaccharides 乐鱼体育官网?
The Global Human Milk Oligosaccharides 乐鱼体育官网 size is expected to reach USD 237.01 million in 2025 and grow at a CAGR of 20.75% to reach USD 608.41 million by 2030.
What is the current Global Human Milk Oligosaccharides 乐鱼体育官网 size?
In 2025, the Global Human Milk Oligosaccharides 乐鱼体育官网 size is expected to reach USD 237.01 million.
Who are the key players in Global Human Milk Oligosaccharides 乐鱼体育官网?
Koninklijke DSM N.V., Chr. Hansen Holding A/S, BASF SE, Inbiose NV and International Flavors & Fragrances Inc. (DuPont) are the major companies operating in the Global Human Milk Oligosaccharides 乐鱼体育官网.
Which is the fastest growing region in Global Human Milk Oligosaccharides 乐鱼体育官网?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global Human Milk Oligosaccharides 乐鱼体育官网?
In 2025, the Asia-Pacific accounts for the largest 乐鱼体育官网 share in Global Human Milk Oligosaccharides 乐鱼体育官网.
What years does this Global Human Milk Oligosaccharides 乐鱼体育官网 cover, and what was the 乐鱼体育官网 size in 2024?
In 2024, the Global Human Milk Oligosaccharides 乐鱼体育官网 size was estimated at USD 187.83 million. The report covers the Global Human Milk Oligosaccharides 乐鱼体育官网 historical 乐鱼体育官网 size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Human Milk Oligosaccharides 乐鱼体育官网 size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Human Milk Oligosaccharides Industry Report
Statistics for the 2025 Global Human Milk Oligosaccharides 乐鱼体育官网 share, size and revenue growth rate, created by Mordor Intelligence鈩� Industry Reports. Global Human Milk Oligosaccharides analysis includes a 乐鱼体育官网 forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
